Product Description
ZG006 is a trispecific antibody against CD3 and two different DLL3 epitopes. The anti-DLL3 end of ZG006 binds to different DLL3 epitopes on the surface of tumor cells, and the anti-CD3 end binds to T cells. ZG006 engages tumor cells and T cells, draws T cells closer to tumor cells, and uses T cells to specifically kill tumor cells. The results of preclinical studies show that ZG006 has a significant tumor inhibitory effect on mouse tumor models, and can cause a significant proportion of mouse tumors to completely regress, indicating that ZG006 has a strong tumor killing effect. ZG006 has shown a good safety profile with low toxic side effects in non-human primates. (Sourced from: https://www.zelgen.com/xinwenzhongxin/2023/07-31/345.html)
Mechanisms of Action: DLL3 Inhibitor, CD3 Inhibitor
Novel Mechanism: No
Modality: Trispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: Suzhou Zelgen
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neuroendocrine Carcinoma|Small Cell Lung Cancer
Phase 2: Oncology Solid Tumor Unspecified|Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06440057 |
ZG006-003 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2026-05-01 |
12% |
2024-12-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07258121 |
ZGGS34-001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2028-12-01 |
12% |
2026-04-29 |
Primary Endpoints|Start Date |
NCT07024277 |
ZG006-005 | P2 |
Not yet recruiting |
Prostate Cancer |
2027-12-01 |
12% |
2025-06-18 |
Primary Endpoints|Treatments |
NCT05978284 |
ZG006-001 | P2 |
Recruiting |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2026-09-01 |
2% |
2026-01-06 |
Primary Completion Date|Primary Endpoints |
NCT06283719 |
ZG006-002 | P2 |
Recruiting |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2026-04-01 |
12% |
2025-11-18 |
Primary Endpoints |
NCT07189455 |
ZG006-006 | P3 |
Recruiting |
Small Cell Lung Cancer |
2028-10-01 |
27% |
2026-01-06 |
|
NCT07231445 |
ZG006-004 | P1 |
Recruiting |
Small Cell Lung Cancer |
2028-12-01 |
50% |
2026-04-29 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT07595913 |
ZG006-009 | P3 |
Not yet recruiting |
Neuroendocrine Carcinoma |
2028-06-01 |
13% |
2026-05-20 |
Primary Endpoints|Treatments |
NCT06592638 |
ZG006US001 | P1 |
Recruiting |
Small Cell Lung Cancer |
2026-12-01 |
50% |
2025-05-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07038096 |
ZG006-ZG005-001 | P2 |
Recruiting |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2027-09-01 |
12% |
2026-01-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|